US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Roundhill GLP-1 & Weight Loss ETF

29.93

-0.2559-0.85%

Post-market: 29.950.0121+0.04%19:30 EDT

Volume:9K

Turnover:279.68K

Market Cap:55.97M

PE:- -

High:30.22

Open:30.22

Low:29.84

Close:30.19

52wk High:37.15

52wk Low:27.34

Shares:1.87M

Float Shares:1.87M

Volume Ratio:0.84

T/O Rate:0.50%

Dividend:0.41

Dividend Rate:1.37%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Sector Update: Healthcare

MT Newswires Live

Novo Nordisk (NVO) Receives a Hold from Jefferies

Viking Therapeutics Stock Surges 36%. it Could Challenge Lilly and Novo's Obesity Empire.

Viking Therapeutics Says Obesity Drug Showed 'Superior' Results in Study; Shares Jump

MT Newswires Live

Hope Fuels Markets but Reality Could Bite

Viking Therapeutics Reports Strong Obesity Drug Maintenance Data

Viking Therapeutics Shares Rise 38% Premarket After Experimental Drug Maintains Weight Loss in Study

THOMSON REUTERS

Viking Therapeutics' Obesity Drug Shows 22% Weight Loss in Study

Viking Therapeutics reports ‘positive’ results from maintenance study of VK2735

Viking Therapeutics Reports Vk2735 Maintenance Trial Keeps up to 97% of Weight Loss with Every-Other-Week Dosing

Viking Therapeutics, - up to 97% Weight Loss Maintained with Every-Other-Week Dosing for Three Months

THOMSON REUTERS

Viking Therapeutics Announces Positive Topline Results from Maintenance Study of Glp-1/Gip Agonist Vk2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens

THOMSON REUTERS

Viking Therapeutics, - Maintenance Dosing Shows Gi Adverse Event Rates Similar to Placebo

THOMSON REUTERS

Viking Therapeutics, - Reports 22% Placebo-Adj Weight Loss at Week 33 with Vk2735 17.5 Mg Weekly Dosing

THOMSON REUTERS

Novo Nordisk Investor Day Disappointed

Market Chatter: Novo Nordisk CEO Eyes M&A to Fill Gaps in Drug Portfolio

MT Newswires Live

Novo Stock (NVO): Deutsche Bank Keeps Sell Rating, Says Growth Strategy ‘Underwhelming on Multiple Fronts’

Novo Nordisk (0QIU) Receives a Hold from Berenberg Bank

Novo Nordisk Investors Remain Nervous, but Share Drop an Overreaction

Novo Nordisk's Underwhelming Investor Day Met with Punishing Response

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/OZEM/news?page=12"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"OZEM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OZEM\",,,,,undefined,":{"symbol":"OZEM","market":"US","secType":"STK","nameCN":"Roundhill GLP-1 & Weight Loss ETF","latestPrice":29.9329,"timestamp":1790971200000,"preClose":30.1888,"halted":0,"volume":9332,"hourTrading":{"tag":"盘后","latestPrice":29.945,"preClose":29.9329,"latestTime":"19:30 EDT","volume":49,"amount":1484.1332,"timestamp":1790983803416,"change":0.0121,"changeRate":0.000404,"amplitude":0},"delay":0,"changeRate":-0.008476653593385642,"floatShares":1870002,"shares":1870002,"eps":0,"marketStatus":"Market Closed","change":-0.2559,"latestTime":"10-02 16:00:00 EDT","open":30.22,"high":30.2224,"low":29.84,"amount":279684.02476400003,"amplitude":0.012667,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":30.1888,"sharesOutstanding":1670000,"nav":30.29,"aum":56642300,"dividendRate":0.013654,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":30.66,"preClose":30.1888,"latestTime":"09:28 EDT","volume":13,"amount":396.459999,"timestamp":1790947684197,"change":0.4712,"changeRate":0.015608,"amplitude":0.005962},"postHourTrading":{"tag":"盘后","latestPrice":29.945,"preClose":29.9329,"latestTime":"19:30 EDT","volume":49,"amount":1484.1332,"timestamp":1790983803416,"change":0.0121,"changeRate":0.000404,"amplitude":0},"volumeRatio":0.8438223402519776,"impliedVol":0.2985,"impliedVolPercentile":0.9124},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OZEM\",,,,,undefined,":{"symbol":"OZEM","floatShares":1870002,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.8438223402519776,"shares":1870002,"dividePrice":0.4087,"high":30.2224,"amplitude":0.012667,"preClose":30.1888,"low":29.84,"week52Low":27.34,"pbRate":"--","week52High":37.15,"institutionHeld":0,"latestPrice":29.9329,"eps":0,"divideRate":0.013654,"volume":9332,"delay":0,"ttmEps":0,"open":30.22,"prevYearClose":34.1569,"prevWeekClose":31.1952,"prevMonthClose":30.79,"prevQuarterClose":30.79,"fiveDayClose":31.1952,"twentyDayClose":33.5876,"sixtyDayClose":33.3949},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OZEM\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"OZEM","amount":0.409914,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Roundhill GLP-1 & Weight Loss ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-31","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2025-12-31"},{"date":"2024-12-30","symbol":"OZEM","amount":0.05307,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-30","defaultRemindTime":1735569000000,"name":"Roundhill GLP-1 & Weight Loss ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-30","currency":"USD","dateTimestamp":1735534800000,"payDate":"2024-12-31"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OZEM\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-30","recordDate":"2024-12-30","paymentDate":"2024-12-31","value":0.05307,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2025-12-31","value":0.409914,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OZEM\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"OZEM\",pageSize:20,pageCount:12,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669935142","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2669935142","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669935142?lang=en_us&edition=fundamental","pubTime":"2026-09-22 21:00","pubTimestamp":1790082001,"startTime":"0","endTime":"0","summary":"Healthcare stocks were mixed pre-bell Tuesday, with the State Street Health Care Select Sector SPDR ETF  0.2% lower and the iShares Biotechnology ETF  up 0.6%.Viking Therapeutics  shares were up more than 23% after the company said its subcutaneous VK2735 showed \"superior weight maintenance\" under less frequent dosing regiments compared to placebo over a 12-week period in a clinical study.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0128526141.USD","BK4588","BK4585","XBI","OZEM","BK4137","IBB","THNR","BK4581","LABU","VKTX","XLV","HCSG","BK4599","LU0029874061.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669142475","title":"Novo Nordisk (NVO) Receives a Hold from Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2669142475","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669142475?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:56","pubTimestamp":1790081803,"startTime":"0","endTime":"0","summary":"Jefferies analyst maintained a Hold rating on Novo Nordisk today and set a price target of $42.20. In addition to Jefferies, Novo Nordisk also rece...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/novo-nordisk-nvo-receives-a-hold-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/novo-nordisk-nvo-receives-a-hold-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU0154236417.USD","NVOC","BK4585","BK4588","NVO","NVOH","OZEM","BK4532","BK4007","LU1093756325.SGD","PPH","NVOX","BK4599","LU1093756168.USD","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669445261","title":"Viking Therapeutics Stock Surges 36%. it Could Challenge Lilly and Novo's Obesity Empire.","url":"https://stock-news.laohu8.com/highlight/detail?id=2669445261","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669445261?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:22","pubTimestamp":1790079720,"startTime":"0","endTime":"0","summary":"Eli Lilly and Novo Nordisk have been locked in a fierce battle to corner the weight-loss market, and while it is effectively a duopoly now emerging competitors could soon challenge their lead.Seizing ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0787776722.HKD","SG9999018865.SGD","ILDR","BK4516","BK4599","ELIS","LU1983299246.USD","LU2237443622.USD","SGXZ81514606.USD","LU2462157665.USD","LU2168564149.EUR","LU2089284900.SGD","LU2168564065.EUR","03165","LU1623119135.USD","LU2023250330.USD","SG9999015952.SGD","IE00B1XK9C88.USD","LU1720051017.SGD","LU0256863902.USD","LU2750360641.GBP","SGXZ31699556.SGD","PJP","MEDX","LU0823416689.USD","LU0109391861.USD","IE00BKVL7J92.USD","SG9999017495.SGD","LU1712237335.SGD","RHHBY","LU0006306889.USD","GB00BDT5M118.USD","LU0174119429.USD","LU1291159041.SGD","SG9999013999.USD","LU0786609619.USD","LU2471134879.HKD","LU1232071149.USD","LU1868837300.USD","BK4532","NVOX","SG9999014906.USD","THNR","LU0354030511.USD","LU0154236417.USD","AGNG","IE00B775H168.HKD","LU2471134523.USD","LU2471134796.USD","LU2063271972.USD","LU0708995401.HKD","IE00BFSS8Q28.SGD","LU2106854487.HKD","LU2491049909.HKD","SG9999014880.SGD","LU2324357040.USD","LU2746668461.USD","LU1551013425.SGD","LU0198837287.USD","LU0061475181.USD","IE00B4JS1V06.HKD","LU1366192091.USD","NVOH","IE00BK4W5M84.HKD","IE0004445015.USD","IE00BKDWB100.SGD","LU0432979614.USD","LU1974910355.USD","LU0097036916.USD","LU2361045086.USD","LU2111349929.HKD","LU2211815571.USD","SG9999015978.USD","IE00BFSS7M15.SGD","LU0203202063.USD","LU2089283258.USD","LU0683600562.USD","LU0820561909.HKD","LU0320765059.SGD","LU1323610961.USD","LU1093756325.SGD","SGXZ57979304.SGD","OZEM","LU2552382215.SGD","LU0820562030.AUD","HRTS","LLYX","LU1548497426.USD","LU0158827781.USD","LU0210536198.USD","LU0079474960.USD","LLII","LU0385154629.USD","IE00BJJMRY28.SGD","CURE","LU1551013342.USD","CANC","LU0466842654.USD","LU1061106388.HKD","LU2357305700.SGD","IHE","LU0417517546.SGD","LU2746668974.SGD","LU0234572021.USD","LU0456855351.SGD","SG9999014898.SGD","LU2360106947.USD","LU0889565916.HKD","LU1280957306.USD","LLY","LU1804176565.USD","IE00BJJMRZ35.SGD","IE0001KFT4U8.USD","BK4534","LU1145028129.USD","LU0823434583.USD","LU1023059063.AUD","LU1868836757.USD","LU0289739699.SGD","LU0345770308.USD","LU0820561818.USD","LU1720051108.HKD","LU1127390331.HKD","LU2417539215.USD","LU2552382132.HKD","LU2750360997.AUD","XLV","LU0225283273.USD","MEDI","TMED","IE00BFTCPJ56.SGD","LU0943347566.SGD","SG9999015945.SGD","LU2087625088.SGD","BK4588","IE00BK4W5L77.USD","LU0114720955.EUR","LU1035775433.USD","LU2756315664.SGD","LU1267930730.SGD","LU2552382058.USD","LU1814569148.SGD","LU2023250504.SGD","IE00BZ1G4Q59.USD","IE00BJJMRX11.SGD","LU2471134952.CNY","LU0471298777.SGD","LU1868836591.USD","LU2236285917.USD","VHT","LU0094547139.USD","LU1691799644.USD","IE00B4R5TH58.HKD","LU0203201768.USD","LU0238689110.USD","BK4533","LU1917777945.USD","LU0256863811.USD","MHIP","LU2361044949.HKD","LU2237438978.USD","LU2462591350.SGD","SGXZ99366536.SGD","IE00B7KXQ091.USD","LU2089984988.USD","LU2264538146.SGD","LU2491050154.USD","LU1069344957.HKD","JDOC","LU2602419157.SGD","LU2108987350.USD","SG9999001176.USD","LU2112291526.USD","LU1988902786.USD","BK4007","LU2237443382.USD","LU2271345857.HKD","BK4139","IE00BKPKM429.USD","SG9999015986.USD","IYH","FTXH","LU1629891620.HKD","LU2028103732.USD","LU0058720904.USD","LU2213496289.HKD","LU0158827948.USD","LU0640476718.USD","LU1868836914.USD","LU2237443895.HKD","LU2265009873.SGD","LU1093756168.USD","LU2756315318.SGD","LU0323591593.USD","LU2168564222.USD","IE00BN29S564.USD","WDNA","FHLC","IE0002141913.USD","LU0882574139.USD","SG9999018857.SGD","SG9999014914.USD","IE00B2B36J28.USD","LU2237443465.HKD","LU0354030438.USD","LU0672654240.SGD","LU2168564495.EUR","LLYZ","LU1989771016.USD","IXJ","VKTX","LU0689472784.USD","IE00BWXC8680.SGD","LU0106261372.USD","IE0004445239.USD","LU0823434740.USD","SGXZ51526630.SGD","LU0964807845.USD","LU2468319806.SGD","LU2896262040.SGD","PPH","LU2491050071.SGD","LU0109394709.USD","LU0882574055.USD","NVO","LU2456880835.USD","TRUH","LU2237443549.SGD","LU0133085943.USD","NVOC","BK4585","IE00B1BXHZ80.USD","LU1057294990.SGD","IE00BJLML261.HKD","IE0005OL40V9.USD","IE00BJT1NW94.SGD","LU0122379950.USD","LU2168563687.JPY","LU2237443978.SGD","LU2023251221.USD","LU2461242641.AUD","LU0266013472.USD","GDOC","LU1064131342.USD","LU1868837136.USD","RXL","LU1979441026.SGD","LU0096364046.USD","LU0353189763.USD","LU0353189680.USD","SG9999001176.SGD","LU0345770993.USD","LU0320765992.SGD","LU0316494557.USD","LU0471298694.HKD","LU2361044865.SGD","BK4581","ELIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144843","title":"Viking Therapeutics Says Obesity Drug Showed 'Superior' Results in Study; Shares Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144843","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144843?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:17","pubTimestamp":1790079477,"startTime":"0","endTime":"0","summary":"Viking Therapeutics  said Tuesday its subcutaneous VK2735 showed \"superior weight maintenance\" under less frequent dosing regiments compared to placebo over a 12-week period in a clinical study.Participants randomized to monthly dosing regimens preserved up to 90% of mean weight loss achieved during the induction period, the company said.VK2735 also demonstrated an \"encouraging safety and tolerability profile,\" Viking said.The company said it plans to explore oral dosing regimens in part 2 of the study.Shares of Viking Therapeutics were up more than 36% in premarket trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["THNR","BK4599","VKTX","BK4585","OZEM","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141342","title":"Hope Fuels Markets but Reality Could Bite","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141342","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141342?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:51","pubTimestamp":1790077860,"startTime":"0","endTime":"0","summary":"Good morning and welcome to another hopeful day for markets as Iran lifts Wall Street's spirits.Stocks looked set to continue their positive start to the week as falling oil prices seemed to offset a ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2347655073.USD","LU2360032135.SGD","BAGY","LU0203345920.USD","AMYY","FAI","LU0210536198.USD","BTC.USD.CC","IE00BK4W5L77.USD","LU0225283273.USD","LU1119994496.HKD","LU0109392836.USD","LU1670710588.SGD","LU2106854487.HKD","XLC","LU1804176565.USD","BK4077","BK4527","LU0738911758.USD","IE00BSNM7G36.USD","IE00BJTD4V19.USD","LU1670711040.USD","WATS","IE00B7SZLL34.SGD","LU1093756325.SGD","IE00BFSS8Q28.SGD","LU0943347566.SGD","LU1066051811.HKD","LU2552382058.USD","LU2420271590.USD","LU0079474960.USD","LU1267930730.SGD","LU0080751232.USD","LU1551013342.USD","IE000YTNTUN2.SGD","LU0198837287.USD","BK4579","SOXY","IE0002270589.USD","SMETAmain","LU0823411888.USD","LU0444973449.USD","LU0784385840.USD","LU1732800096.USD","GBTC","XDAT","LU2463028550.USD","LU1564329032.USD","WANT","LU1074936037.SGD","DEFI","INTW","LU0106261372.USD","BK4141","LU0787776722.HKD","LU0211327993.USD","LU0130517989.USD","TSLA","LU1670710661.SGD","LU1979441026.SGD","CHAT","IE00BMPRXN33.USD","LU1697837992.HKD","BTCZ","IE0000B7K699.USD","BK4585","IE00B7KXQ091.USD","LU1242518857.USD","IE00B4YYXB79.USD","CBTA","LU1852331112.SGD","LU1718418525.SGD","LU2108987350.USD","SG9999017495.SGD","IE000BZT7R73.USD","IE000KEQY171.SGD","LU0265550359.USD","IE000M9KFDE8.USD","LU1571399168.USD","TSDD","LU1732799900.SGD","IE0009G5SDU7.USD","LU1992135399.USD","LU2403377893.USD","LU2860962120.EUR","LU0979878070.USD","TEST","IE00BMPRXR70.SGD","LU1935043452.HKD","FBTC","IE00B3SWFQ91.USD","LU2764263203.CNY","LU1429558221.USD","LU2461242641.AUD","BTCL","BK4099","LU0234570918.USD","LU2089985449.USD","LU1880398471.USD","LU1496350502.SGD","IETC","LU1564329115.USD","IE00B1XK9C88.USD","LU0742534661.SGD","LU0912757837.SGD","LU2456880835.USD","LU2417539215.USD","LU1242518931.SGD","SG9999015952.SGD","LU1093756168.USD","LU2896262040.SGD","LU1670711123.USD","LU1935042488.USD","CBXA","LU1803068979.SGD","LU2746668974.SGD","LU2065169927.USD","QQQA","BETE","LU0353189763.USD","LU0353189680.USD","LU2552382132.HKD","LU0417517546.SGD","SGXZ80539844.SGD","BK4574","TLA","CBOA","LIT","PARA","LU2236285917.USD","LU2265009873.SGD","RSPC","SG9999004303.SGD","BCCC","LU0068578508.USD","LU2054465674.USD","MAXI","GB00B4QBRK32.GBP","TESL","LU0256863811.USD","LU1989772840.SGD","LU0070217475.USD","BITB","LU2023250330.USD","LU0354030511.USD","LU0552385451.USD","BK4529","LU2242649171.HKD","LU0823421333.USD","VOX","BK4108","LU2361044949.HKD","CBOJ","IE00B5949003.HKD","LU1564329461.SGD","METU","09366","LU0061474705.USD","LU2430703251.USD","IE0034235303.USD","LU2543165471.USD","LU2458330243.SGD","BK4566","BTCC","LU1066051498.USD","BK4524","CBXY","TSLG","IE00BQXX3F31.USD","BTF","LU2213496289.HKD","LU0210528500.USD","LU2133065610.SGD","LU0640476718.USD","LU2381873111.SGD","09766","AMDD","BTRN","LU1116320901.HKD","LU0187121727.USD","SGXZ81514606.USD","CRSH","SG9999015986.USD","LU2360106780.USD","LU0256863902.USD","BK4535","LU2404859741.USD","IBIT","LU0784384876.USD","TSII","IE00B19Z8X17.USD","TESC","LU1989772923.USD","QBF","LU1003077747.HKD","TEK","LU0345770308.USD","LU2505996509.AUD","LU0308772762.SGD","BK4599","TSLL","LU2168564495.EUR","LU0109391861.USD","BK4602","LU0321505868.SGD","LU0056508442.USD","HK0000304805.HKD","LU0096362180.USD","LU1839511570.USD","BTCI","FTXL","LU0048584097.USD","AIS","SAMD0main","BK4550","LU1791710400.SGD","BITX","LU2272731600.USD","OZEM","LU0154236417.USD","LU1642822529.SGD","AMDL","LU2487616109.SGD","LU0672654240.SGD","XBTY","LU0267386448.USD","GB00BDT5M118.USD","LU2237957902.USD","IE00B19Z8W00.USD","LU1699723380.USD","LU1674673691.USD","LU0251142724.SGD","NVOX","BK4516","LU2764262908.HKD","SGXZ23171101.USD","LU0985489474.SGD","LU0444971666.USD","MNRS","LU2462591350.SGD","NULC","METG","LU0048573561.USD","SOXX","LU0310800965.SGD","LU1935042215.USD","LU1267930813.SGD","WISE","IE0005OL40V9.USD","LU0354030438.USD","AMDC","WBD","LU0072462426.USD","BITI","TRUC","TSL","CBTY","BETH","BITU","BFAP","IE00BJLML261.HKD","LU0823434740.USD","IE00B19Z3581.USD","LU2097829019.USD","LU2023250504.SGD","USXF","LU0310799852.SGD","BK4588","LU1366192091.USD","TSLP","LU0323591593.USD","BK4548","SGXZ31699556.SGD","LU1235294995.USD","07366","SG9999001077.SGD","LU0011850046.USD","BFJL","BK4511","LU1935042991.SGD","LU2756315664.SGD","LU2462157665.USD","IE00BKVL7J92.USD","IE000MB6IJN5.SGD","LU0949170772.SGD","IDRV","FBY","LU0128525689.USD","LU1868837136.USD","TRFK","INTC","FBL","AMUU","LU0251132253.USD","LU0149725797.USD","LU1861220033.SGD","FBYY","LU0957808578.USD","LU1989764748.USD","SG9999002232.USD","LU2471134952.CNY","TTEQ","LU0061474960.USD","BK4592","IE00B19Z3B42.SGD","METQ","LU0642271901.SGD","LU0251131958.USD","LU2098885051.SGD","METW","EZBC","LU2125154935.USD","LU2247934214.USD","LINT","LU2272731865.HKD","AMDS","BK4555","BK4605","BRRR","BK4007","BK4614","LU1868836914.USD","LU1267930490.SGD","IE00BQXX3C00.GBP","LU1814569148.SGD","LU1923623000.USD","CBTO","BTCO","IE00B4JS1V06.HKD","CBOY","LU1059921491.USD","BK4573","LU0321505439.SGD","HK0000914660.USD","IE000WAW04H5.SGD","LU0072461881.USD","LU0661504455.SGD","INT","LU0476273544.USD","BAI","LU0265550946.USD","LU1868836591.USD","LU1992135472.HKD","IE00BJTD4N35.SGD","LU1670627923.USD","LU2602419157.SGD","AMDW","LU0157215616.USD","LU1868837300.USD","IE00B19Z9505.USD","BITO","LU0211331839.USD","IE00BK4W5M84.HKD","LU2357305700.SGD","LU2063271972.USD","LU1720051108.HKD","BK4507","LU0433182093.SGD","LU1815336760.USD","LU0820561818.USD","LU1935043023.USD","TSLS","LU0795875169.SGD","LU0708995401.HKD","LU0784385170.HKD","LU0203347892.USD","LU2750360641.GBP","BITY","LU1316542783.SGD","LU1868836757.USD","LU1232071149.USD","BK4581","LU0882574139.USD","LU2322448957.HKD","LU2168564065.EUR","TSLZ","TSLT","LU0786609619.USD","LU2552382215.SGD","BK4604","IE0001KFT4U8.USD","LU1823568750.SGD","LU1988902786.USD","SG9999002224.SGD","LEGR","IE0003U64NQ7.SGD","LU0348723411.USD","LU1153585028.USD","TSLY","LU0314104364.USD","NVO","LU1280957306.USD","LU0726765562.USD","STSLAmain","LU0210533765.USD","DRIV","IE00BMPRXQ63.HKD","LU1201861249.SGD","NVOH","LU1670628061.USD","LU1674673428.USD","BK4554","LU2756315318.SGD","THNR","LU1974910355.USD","XNTK","LU1861558580.USD","LU1778281490.HKD","LU2720916845.USD","LU0689472784.USD","GXPC","IE000ITXATA3.USD","LU0211328371.USD","LU1303367103.USD","OGIG","SOCL","LU1046421795.USD","IE0004445015.USD","LU2168563687.JPY","LU1564329628.SGD","ILDR","SG9999014914.USD","IE00BFSS7M15.SGD","SG9999014906.USD","GB00B4LPDJ14.GBP","LU2430703178.SGD","LU2065170008.USD","AIQ","SMHX","LU2430703095.HKD","BK4575","LU0957791311.USD","BK4533","LU0648001328.SGD","LU2355687059.USD","GAMR","LU0127658192.USD","IE00B775H168.HKD","IE00BJJMRX11.SGD","LU1069344957.HKD","LU2148611432.USD","IE00BN29S564.USD","LU2237957811.SGD","TSLI","IE000W1ABFV2.USD","LU2326559502.SGD","BTCW","IE00BZ1G4Q59.USD","LU0170899867.USD","NVOC","TSLO","LU0466842654.USD","LU2458330169.SGD","INYY","LU0345769631.USD","LU0528227936.USD","IE000SO60NU8.SGD","LU2168564222.USD","FBX","LU0208291251.USD","LU2249611893.SGD","LU0553294199.USD","AMDU","LU0719512351.SGD","LU0859254822.USD","LU1084165304.USD","LU2250418816.HKD","LU1917777945.USD","LU2505996681.GBP","ARTY","LU2471134523.USD","LU1935043536.SGD","LU2317271919.USD","LU0081259029.USD","METD","TSLQ","ELOL","LU0820561909.HKD","LU0878866978.SGD","SGXZ99366536.SGD","BK4512","LU2023250843.SGD","LU1951200564.SGD","BK4598","LU0061475181.USD","LU2471134796.USD","SG9999014898.SGD","LU0097036916.USD","LU0130102774.USD","IE0004445239.USD","LU2471134879.HKD","LU0823421416.USD","BK4551","HK0000914686.HKD","LU1951198990.SGD","LU2264538146.SGD","LTL","LU1861215975.USD","LU0690374615.EUR","LU1914381329.SGD","LU1127390331.HKD","DFII","BK4612","LU0006306889.USD","LU0985320562.USD","SG9999018865.SGD","LU0316494557.USD","LU0345769128.USD","LU1064131342.USD","SINTCmain","BK4543","LU0077335932.USD","LU0690374961.EUR","LU1366333091.USD","LU1551013425.SGD","FDRV","IE00BKDWB100.SGD","04335","LU1791710582.SGD","CBTJ","BK4587","LU1489326972.SGD","LU0276348264.USD","LU2750360997.AUD","AMDY","CBOO","SMOG","LU0174119429.USD","LU2404859667.USD","BK4125","LU0082616367.USD","CHPS","LU2931357623.SGD","LU1629891620.HKD","LU0788109477.HKD","BK4534","LU0683600562.USD","TSLR","IE000F7OJYX1.SGD","IE00BWXC8680.SGD","LU2087621335.USD","LU2361044865.SGD","LU1435385759.SGD","LU0162691827.USD","LU1066053197.SGD","LU0889565833.HKD","YBTC","LU2087625088.SGD","LU2244417387.USD","LU0823434583.USD","LU1301847155.USD","LU1261432733.SGD","LU2746668461.USD","LU1066051225.USD","LU0477156953.USD","LU2242650005.HKD","LU1861559042.SGD","LU2347655156.SGD","LU2361045086.USD","ARKB","IE0034235188.USD","BK4532","IE0009356076.USD","LU1989764664.SGD","LU1720051017.SGD","LU0980610538.SGD","LU2592432038.USD","AMDG","LU1035775433.USD","LU0792757196.USD","LU2290526834.HKD","LU0889566641.SGD","SG9999015978.USD","LU2125154778.USD","LU1145028129.USD","WUGI","AMD","LU0096364046.USD","LU0795875086.SGD","SG9999018857.SGD","LU2473716301.USD","SG9999014880.SGD","HODL","LU0053666078.USD","LU0234572021.USD","SGXZ51526630.SGD","LU2272731782.SGD","LU0390134368.USD","CBXJ","IE00B1BXHZ80.USD","BK4515","LU0274383776.USD","LU0823414478.USD","LU2065171311.SGD","IE00BJJMRY28.SGD","LU0345770993.USD","DAMD","IE00BQXX3D17.EUR","PPH","SG9999015945.SGD","LU0545039389.USD","TSYY","LU2168564149.EUR","FCOM","LU0784383803.USD","META","BTC","PSI","LU2360107168.USD","LU2357627491.SGD","LU1116320737.USD","LU2065171402.SGD","SBIT","BPI","LU0215105999.USD","LU0724617625.USD","LU0070302665.USD","LU1267930227.SGD","SMH","BK4023","LU0052756011.USD","SG9999001424.SGD","LU0133085943.USD","07766","LU0820562030.AUD","LU0320765059.SGD","LU0203201768.USD","LU0320765489.SGD","LU2322448791.USD","LU1548497426.USD","CBXO","LU0964807845.USD","TSLW","LU0949170426.SGD","HK0000304797.USD","LU0203202063.USD","LU1880398554.USD","LU1815333072.USD","METV","LU2764263039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669227149","title":"Viking Therapeutics Reports Strong Obesity Drug Maintenance Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2669227149","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669227149?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:30","pubTimestamp":1790076623,"startTime":"0","endTime":"0","summary":"Viking Therapeutics ( ($VKTX) ) has issued an announcement. On September 22, 2026, Viking Therapeutics reported positive top-line data from a maint...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/viking-therapeutics-reports-strong-obesity-drug-maintenance-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/viking-therapeutics-reports-strong-obesity-drug-maintenance-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OZEM","BK4139","BK4588","VKTX","BK4585","THNR","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669149350","title":"Viking Therapeutics Shares Rise 38% Premarket After Experimental Drug Maintains Weight Loss in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2669149350","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669149350?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:19","pubTimestamp":1790075970,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E0CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","VKTX","BK4585","BK4139","THNR","BK4588","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669146733","title":"Viking Therapeutics' Obesity Drug Shows 22% Weight Loss in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2669146733","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669146733?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:12","pubTimestamp":1790075521,"startTime":"0","endTime":"0","summary":"Viking Therapeutics' obesity drug shows 22% weight loss in studySept 22 (Reuters)-Viking TherapeuticsVKTX.Osaid on Tuesday its experimental GLP-1 obesity drug helped patients lose 22% of their body weight after 33 weeks of weekly treatment in a maintenance study.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4N45E0OG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","BK4588","BK4599","BK4585","VKTX","THNR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669493381","title":"Viking Therapeutics reports ‘positive’ results from maintenance study of VK2735","url":"https://stock-news.laohu8.com/highlight/detail?id=2669493381","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669493381?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:10","pubTimestamp":1790075445,"startTime":"0","endTime":"0","summary":"Viking Therapeutics (VKTX) announced positive top-line results from the company’s maintenance study of VK2735, the company’s dual agonist of the gl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/viking-therapeutics-reports-positive-results-from-maintenance-study-of-vk2735-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/viking-therapeutics-reports-positive-results-from-maintenance-study-of-vk2735-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4599","VKTX","BK4588","THNR","BK4585","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669179146","title":"Viking Therapeutics Reports Vk2735 Maintenance Trial Keeps up to 97% of Weight Loss with Every-Other-Week Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2669179146","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669179146?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:05","pubTimestamp":1790075134,"startTime":"0","endTime":"0","summary":"Viking Therapeutics reports VK2735 maintenance trial keeps up to 97% of weight loss with every-other-week dosingViking Therapeutics reported positive topline results from a maintenance study of obesit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL3vJdWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","OZEM","THNR","BK4585","BK4139","VKTX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669514611","title":"Viking Therapeutics, - up to 97% Weight Loss Maintained with Every-Other-Week Dosing for Three Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2669514611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669514611?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:05","pubTimestamp":1790075100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUABKSRFB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","VKTX","OZEM","BK4588","THNR","BK4599","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669461111","title":"Viking Therapeutics Announces Positive Topline Results from Maintenance Study of Glp-1/Gip Agonist Vk2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens","url":"https://stock-news.laohu8.com/highlight/detail?id=2669461111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669461111?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:05","pubTimestamp":1790075100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUABKSRFB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VKTX","THNR","BK4585","BK4139","BK4599","BK4588","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669146116","title":"Viking Therapeutics, - Maintenance Dosing Shows Gi Adverse Event Rates Similar to Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2669146116","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669146116?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:05","pubTimestamp":1790075100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUABKSRFB:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4139","BK4588","VKTX","BK4599","OZEM","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669112146","title":"Viking Therapeutics, - Reports 22% Placebo-Adj Weight Loss at Week 33 with Vk2735 17.5 Mg Weekly Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2669112146","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669112146?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:05","pubTimestamp":1790075100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUABKSRFB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VKTX","THNR","BK4585","BK4139","BK4599","BK4588","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451651","title":"Novo Nordisk Investor Day Disappointed","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451651","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669451651?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:39","pubTimestamp":1790073540,"startTime":"0","endTime":"0","summary":"1038 GMT - Novo Nordisk's capital markets day announcements, including the diversification plan and a vague midterm sales target, disappointed investors, AlphaValue analyst Abhishek Raval writes. \"Against the backdrop of excessive dependency on a single molecule, aggressive and heavy diversification bets, along with impeccable commercial execution, are the need of the hour.\" However, the markets have their reservations, Raval says. The commercial success of oral Wegovy, some promising late-stage assets, and the firepower for acquisitions provide reasons to bet on Novo, which is available at a discount to peers, he adds. AlphaValue rates the Danish drugmaker's stock at buy with a 450 Danish kroner target price. Shares fall 0.2% to 259.40 kroner.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKVL7J92.USD","LU1093756325.SGD","LU1093756168.USD","BK4532","BK4588","IE00BZ1G4Q59.USD","NVOX","NVOH","BK4599","OZEM","PPH","NVO","NVOC","BK4007","THNR","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669713148","title":"Market Chatter: Novo Nordisk CEO Eyes M&A to Fill Gaps in Drug Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2669713148","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669713148?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:52","pubTimestamp":1790070723,"startTime":"0","endTime":"0","summary":"Novo Nordisk  Chief Executive Mike Doustdar said the pharmaceutical major is considering acquisitions to bolster its position in the weight-loss drug market, CNBC reported Tuesday, citing an interview.Doustdar said Novo Nordisk will look for weaknesses in its drug lineup and consider acquisitions of treatments that could help close those gaps, CNBC reported.Doustdar said that the market reaction to its new long-term strategy and growth targets showed that the company still has work to do in convincing some investors.Novo Nordisk did not immediately reply to MT Newswires' request for comment.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BKVL7J92.USD","BK4588","LU1093756325.SGD","NVOC","IE00BZ1G4Q59.USD","NVOX","BK4585","PPH","THNR","BK4532","NVOH","BK4007","OZEM","NVO","LU1093756168.USD","BK4599","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143804","title":"Novo Stock (NVO): Deutsche Bank Keeps Sell Rating, Says Growth Strategy ‘Underwhelming on Multiple Fronts’","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143804","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143804?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:43","pubTimestamp":1790070183,"startTime":"0","endTime":"0","summary":"Novo shares fell 7.96% to $39.80 on Monday after its growth strategy, disclosed at its Capital Markets Day in London, failed to impress investors\n...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/novo-stock-nvo-deutsche-bank-keeps-sell-rating-says-growth-strategy-underwhelming-on-multiple-fronts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/novo-stock-nvo-deutsche-bank-keeps-sell-rating-says-growth-strategy-underwhelming-on-multiple-fronts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","LU1093756325.SGD","BK4585","BK4599","THNR","NVOX","IE00BZ1G4Q59.USD","NVOC","OZEM","NVO","PPH","BK4588","BK4007","LU1093756168.USD","LU0154236417.USD","NVOH","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486461","title":"Novo Nordisk (0QIU) Receives a Hold from Berenberg Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669486461?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:15","pubTimestamp":1790068532,"startTime":"0","endTime":"0","summary":"In a report released today, Kerry Holford from Berenberg Bank maintained a Hold rating on Novo Nordisk, with a price target of DKK305.00. Holford c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/novo-nordisk-0qiu-receives-a-hold-from-berenberg-bank-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/novo-nordisk-0qiu-receives-a-hold-from-berenberg-bank-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BKVL7J92.USD","BK4588","LU1093756325.SGD","BK4599","OZEM","THNR","NVO","NVOH","BK4007","NVOX","IE00BZ1G4Q59.USD","LU0154236417.USD","NVOC","PPH","BK4585","BK4532","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669110697","title":"Novo Nordisk Investors Remain Nervous, but Share Drop an Overreaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2669110697","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669110697?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:11","pubTimestamp":1790068260,"startTime":"0","endTime":"0","summary":"0909 GMT - Novo Nordisk's 8% share price fall following the investor day is an overreaction, but proves that investors remain nervous about 2027, with expected price pressure and CagriSema drug launch skepticism, Berenberg analysts write. The Novo story appears more interesting from 2028, with zenagamtide phase 3 data, CagriSema bone and muscle function data and multiple phase 1 and 2 readouts, the bank says. The event provided a comprehensive overview of the company's strategy, R&D pipeline and business operations, but offered only incremental strategic insights, it adds. The 2030 and 2035 sales ambitions were also outlined, which are broadly in line with expectations. Understanding the need to quickly diversify the portfolio ahead of U.S./EU semaglutide patent expiry early next decade, Novo aims to significantly speed up development and supplement the internal pipeline. Shares fall 0.7%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU1093756325.SGD","BK4585","BK4599","THNR","NVOX","IE00BZ1G4Q59.USD","NVOC","OZEM","NVO","PPH","BK4588","BK4007","LU1093756168.USD","LU0154236417.USD","NVOH","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141741","title":"Novo Nordisk's Underwhelming Investor Day Met with Punishing Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141741","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141741?lang=en_us&edition=fundamental","pubTime":"2026-09-22 15:41","pubTimestamp":1790062860,"startTime":"0","endTime":"0","summary":"0740 GMT - Novo Nordisk's investor day underwhelmed on multiple fronts, relative to some of the more optimistic expectations heading into the event, Deutsche Bank analyst Emmanuel Papadakis writes. \"Whilst the event provided both a helpful and thorough review of the business outlook as well as a strategic refresh, it was met with a fairly punishing market response.\" The bank says there was largely a reiteration of familiar strategic messaging and the mid-term building blocks, in addition to somewhat underwhelming mid-term guidance. There was also nothing of substance in terms of clinical data or assets, and little clarity on M&A even though it clearly remains on the agenda, Deutsche Bank adds. The bank lowers its stock target price to 245 Danish kroner from 265 kroner and retains its sell rating. Shares fall 0.6% to 258.50 kroner.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","BK4588","LU1093756325.SGD","NVOC","IE00BZ1G4Q59.USD","NVOX","BK4585","PPH","THNR","BK4532","NVOH","BK4007","OZEM","NVO","LU1093756168.USD","BK4599","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":12,"totalSize":285,"code":"91000000","status":"200"}]}}